Business Context and Reporting Period
This Form 8-K was filed by Inhibikase Therapeutics, Inc. on January 24, 2023. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Atlanta, Georgia. Its common stock trades on The Nasdaq Capital Market under the symbol "IKT".
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
The Company received a deficiency letter from Nasdaq on July 25, 2022, due to its common stock trading below the $1.00 minimum bid price requirement for 30 consecutive business days. On January 24, 2023, Nasdaq granted the Company an additional 180-day compliance period, extending until July 24, 2023, to regain compliance.
Outlook, Risks, and Contingencies
- Compliance Path: The Company intends to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.
- Delisting Risk: If the closing bid price does not reach at least $1.00 per share for 10 consecutive business days by July 24, 2023, Nasdaq will notify the Company that its stock will be delisted.
- Appeal Rights: In the event of delisting, the Company may appeal the determination to a Hearings Panel.
- Other Standards: The Company meets all other Nasdaq initial listing standards, including the market value of publicly held shares.
Investor Verification Checklist
- Verify the current trading price of IKT to assess proximity to the $1.00 threshold.
- Monitor for any announcements regarding the execution of a reverse stock split.
- Confirm the Company's cash position to ensure it can sustain operations while addressing the listing deficiency.
- Review the Company's pipeline progress, as the filing does not disclose operational or clinical updates.